teva_copy

Teva terminates Ajovy at Phase 3 in episodic cluster headache

pharmafile | April 24, 2019 | News story | Research and Development Teva, ajovy, headache, pharma 

Israeli pharmaceutical firm Teva has announced its intention to terminate further development of its calcitonin gene-related peptide (CGRP) inhibitor Ajovy (fremanezumab) in the treatment of episodic cluster headaches after it became apparent that the drug is unlikely to meet its primary endpoint at Phase 3.

Conclusions drawn from a pre-specified futility analysis of the Phase 3 ENFORCE study indicated that Ajovy would not adequately improve mean change from baseline in the weekly average number of cluster headache attacks during the 4-week treatment period, so the drugmaker has decided to discontinue the trial.

Despite the decision, Teva made clear that it would still pursue other applications of Ajovy, particularly in the treatment of post-traumatic headache, which is currently being evaluated at Phase 2.

“We’d like to thank the patients and investigators for their immense contributions to this study,” remarked Dr Tushar Shah, Senior Vice President, Head of Global Specialty Clinical Development at Teva. “Despite these results, we are continuing to evaluate if fremanezumab treatment can provide clinical benefits in additional diseases where anti-calcitonin gene-related peptide (CGRP) therapy may play a role in its pathophysiology.”

Matt Fellows

Related Content

Teva Pharmaceuticals shares phase 3 data for Ajovy as migraine treatment

Teva Pharmaceuticals has announced data from a post hoc analysis of two phase 3 clinical …

louis-reed-pwckf7l4-no-unsplash_5

Sanofi and Teva partner for development of inflammatory bowel disease treatment

Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation …

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Latest content